Corrigendum to “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3⁺ CD8⁺ T Cells and Survival in Diffuse Large B Cell Lymphoma”

In the article titled “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3⁺ CD8⁺ T Cells and Survival in Diffuse Large B Cell Lymphoma” [1], the survival data for the Tim-3⁺ TIL and Tim-3⁻ TIL groups was mistakenly reversed by the authors during manuscript preparation. The following sections should be corrected.

1. The abstract section should be corrected from:

“Multiplexed immunofluorescence revealed that patients with Tim-3-expressing tumor-infiltrating lymphocytes (Tim-3⁺ TILs) exhibited poor outcomes than those with Tim-3⁻ TILs (p = 0.041). The median survival times of these patients were 65.0 (95% confidence interval (CI): 71.2–88.6) and 79.9 months (95% CI: 54.4–75.6), respectively.”

To:

“Multiplexed immunofluorescence revealed that patients with Tim-3-expressing tumor-infiltrating lymphocytes (Tim-3⁺ TILs) exhibited poor outcomes than those with Tim-3⁻ TILs (p = 0.041). The median survival times of these patients were 65.0 (95% confidence interval (CI): 54.4–75.6) and 79.9 months (95% CI: 71.2–88.6), respectively.”

• (ii) Section 3.4, “Prognostic value of Tim-3⁺ TILs and exhausted Tim-3⁺ CD8⁺ T cells in DLBCL,” should be corrected from:

“The median survival times for patients with Tim-3⁺ TILs and Tim-3⁻ TILs were 65.0 (95% confidence interval (CI): 71.2–88.6) and 79.9 months (95% CI: 54.4–75.6), respectively.”

To:

“The median survival times for patients with Tim-3⁺ TILs and Tim-3⁻ TILs were 65.0 (95% confidence interval (CI): 54.4–75.6) and 79.9 months (95% CI: 71.2–88.6), respectively.”